4.5 Article

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Radiology, Nuclear Medicine & Medical Imaging

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

Martin Eiblmaier et al.

JOURNAL OF NUCLEAR MEDICINE (2008)

Review Radiology, Nuclear Medicine & Medical Imaging

PET versus SPECT: strengths, limitations and challenges

Arman Rahmim et al.

NUCLEAR MEDICINE COMMUNICATIONS (2008)

Article Radiology, Nuclear Medicine & Medical Imaging

Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer

Lakshmi Sampath et al.

JOURNAL OF NUCLEAR MEDICINE (2007)

Article Radiology, Nuclear Medicine & Medical Imaging

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft

Wouter B. Nagengast et al.

JOURNAL OF NUCLEAR MEDICINE (2007)

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using In-111-trastuzumab (Herceptin) Fab fragments

Y Tang et al.

NUCLEAR MEDICINE AND BIOLOGY (2005)

Article Pharmacology & Pharmacy

Preclinical characterisation of 111In-DTPA-trastuzumab

MN Lub-de Hooge et al.

BRITISH JOURNAL OF PHARMACOLOGY (2004)

Review Radiology, Nuclear Medicine & Medical Imaging

Clinical applications of PET in oncology

EM Rohren et al.

RADIOLOGY (2004)

Article Radiology, Nuclear Medicine & Medical Imaging

Production of therapeutic quantities of 64Cu using a 12 MeV cyclotron

A Obata et al.

NUCLEAR MEDICINE AND BIOLOGY (2003)

Article Oncology

Cancer prevalence in European registry areas

A Micheli et al.

ANNALS OF ONCOLOGY (2002)

Review Oncology

HER2/neu expression in malignant lung tumors

FR Hirsch et al.

SEMINARS IN ONCOLOGY (2002)

Article Medicine, General & Internal

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

DJ Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)